Cambridge-based biotechnology company developing next-generation RNA therapeutics for complex diseases. The company is pioneering a multi-RNA combination medicine platform designed to target multiple biological pathways simultaneously, addressing conditions where single-target approaches may be insufficient. By combining RNA biology, advanced delivery technologies, and AI-enabled therapeutic design, Symphorna aims to create programmable treatments with applications across areas such as fibrosis, inflammatory disease, and other conditions driven by complex biological mechanisms. Through its innovative RNA platform, the company is working to accelerate the development of more precise and effective medicines for patients with significant unmet medical needs.